Abstract: A discriminant analysis model is presented for carcinogenic risk. The data set is obtained from the two-year rodent study FDA/CDER database and was divided into a training set of 1022 organic compounds and an external validation test set of 50 compounds. The model is designed to use as a decision support tool for a defined decision threshold, and is thus a binary discrimination into "high risk" and "low risk" categories. The carcinogenic risk classification is based on the method for estimating human risk from two-year rodent studies developed at the FDA/CDER/ICSAS. The paradigm chosen for this model allows a straightforward risk analysis based on historic information, as well as the computation of coverage, probability and confidence metrics that can further qualify the computed result. The molecular structures were represented as MDL mol files. The molecular structure information was obtained as topological structure descriptors, including atom-type and group-type E-State and hydrogen E-State indices, molecular connectivity chi indices, topological polarity, and counts of molecular features. The MDL ® QSAR software computed all these descriptors. Furthermore, the discriminant analyses were all performed with the MDL ® QSAR software. The reported model is based on fifty-three descriptors, using the nonparametric normal kernel method and the Mahalanobis distance to determine proximity. The model performed very well on the fifty compounds of the test set, yielding the following statistics: 76% correctly classified "high risk" (carcinogenic) and 84% correctly classified as "low risk" (non-carcinogenic).
I. INTRODUCTION AND BACKGROUND
Rodent carcinogenicity studies are required for the marketing of most chronically administered drugs. These studies are the most costly and time-consuming non-clinical regulatory testing requirement in the development of a drug. The cost is approximately $2 million for a rat and mouse study, requiring 2 years of treatment, and at least an additional 1-2 years for histopathological analysis and report writing. The human carcinogenic potential of a compound is a property that cannot be evaluated in clinical trials and therefore safety decisions are made mainly on the basis of animal study results and risk/benefit considerations. The results of rodent carcinogenicity studies can have considerable impact on drug approvability. Even when rodent carcinogenicity findings do not prevent marketing, they can seriously restrict the marketing of some products or reduce their competitive advantage. Rodent carcinogenicity studies are usually initiated relatively late in drug development when considerable resources and have already been invested in a potential new product. Significant carcinogenic findings at this stage of drug development can have disastrous and costly consequences for both the sponsoring company and the regulatory agency in the form of additional review cycles and time and effort invested in failed applications. Predictive modeling can reduce the likelihood of developing a compound that produces significant rodent tumors and can, therefore, lead to significant savings for both the pharmaceutical industry and the regulatory agency. The rodent carcinogenicity bioassay is also a pivotal component of food safety and environmental regulatory policy.
Ready access to scientific knowledge is critical to support safety-related regulatory and product development decisions, particularly in situations where available experimental information is inadequate or unavailable, to identify information gaps, and to prioritize research. A current challenge is the development of better means to identify useful relationships and insights from large sets of data. Based on the major advances in computer technology, chemoinformatics, and predictive toxicology, the accumulated results of rodent carcinogenicity studies in public databases and FDA files can be more effectively used to improve the scientific basis of regulatory and product development decisions and reduce the use of animals in testing. It is conceivable that over time with increased experience and confidence in carcinogenicity predictive software, it may be possible to reduce carcinogenicity testing for compounds that have molecular structures that are highly represented in the carcinogenicity database. This process would reduce unnecessary testing and also free resources for testing compounds that are truly new molecular entities and are poorly represented in the carcinogenicity database.
In recent years methods have been developed for grouping together molecules with similar molecular structures, based on the use of topological structure information. Over the past decade there has been a significant growth in the use of similarity-based searching of databases in drug design and these methods have been shown to have a broader application [1] [2] [3] [4] . The objective has been to organize a database of molecules according to a set of structure criteria so that compounds can be identified as being similar to a reference or target molecule. These similar compounds become candidates for screening or further analysis in the design process. The rationale is that compounds that are similar to a reference molecule are likely to be related to the behavior of the reference molecule in some sense. With the growth of combinatorial chemistry, the compounds in a database may be entirely or partially virtual; in other words, they are synthesized in silico. As a result, there may be no property value information with the molecules; hence, similarity is based entirely on the structural descriptions chosen in a particular study. There is thus no useful way of evaluating similarity based on physical properties except by virtue of the future success of the drug design project employing this general method.
Lajiness has shown quite clearly that a random search through a list of molecules is inferior to a search through an organized database, based on its ability to generate similarity or diversity in a study [3] . Some form of encoding structure information should be present for meaningful exploitation of a database. The code of structure information thus becomes the metric to evaluate similarity or its complement, diversity. This approach is not an exercise in multi-parameter QSAR modeling. With virtual molecules, many or all of the property values are unknown. The search is conducted by selecting a set of descriptors deemed important and finding the relation of molecules relative to a reference molecule using a metric such as distance or a grouping such as nearest neighbors. The objective is to create a cluster of molecules of potential interest based on several structure indices. Interesting compounds may appear that can be selected for screening or for further applications in the database search process.
The encoding and subsequent searching can be a browsing process, using electrotopological state indices (EState) values or other information-rich indices, such as molecular connectivity, removing the need for carefully delineated structural features which may be unknown or which can severely limit diversity. The choice of limiting distance values among molecules in the database makes it possible to reduce the number of output molecules. A qualitative advantage of this process is the stimulation of the chemist's imagination [5] .
A large number of descriptors are available to be employed in the organization of a database. It is not our intention here to create a list of these or to make comparisons, each method being suitable for different circumstances. Our intention however is to build on the use of atom-type E-State descriptors along with molecular connectivity indices as a systematic organizer of a database, imparting a rich information source that can produce potentially useful structure patterns [6] [7] [8] . This present study requires that the structure representation employed be able to organize the data set molecules in such a way that those with high potential for a particular property (i.e. carcinogenic risk) be more closely associated with each other than with those that are associated with another property such as low carcinogenic risk. Previous work appears to indicate such a possibility [6] [7] [8] [9] . The ability of the simple molecular connectivity indices to organize a set of skeletal structures has been demonstrated [9] . Molecular skeletons are grouped in a meaningful manner. Furthermore directions within the representation space have meaning in terms of significant chemical information such as degree of skeletal branching, adjacency of branch points, and number of rings and types of fused ring systems. The atom-type E-State structure descriptors have also been shown to organize molecular structures in a chemically meaningful manner, emphasizing electronic information [10, 11] . Based on the structure space provided by the atom type E-State descriptors, excellent similarity searches through a chemical database have been reported [7, 8, 10] . This combination of structure information representations provided the basis for the use of structure similarity methods together with topological descriptors that have recently been applied to QSAR modeling of rodent carcinogenicity [12] .
The result of these investigations indicates that the use of the atom-type E-State descriptors together with the molecular connectivity chi indices provides a structure space in which molecular structures are organized in chemically meaningful ways so that carcinogenic properties associated with those structures can also be expected to be usefully organized. As a result, statistical methods of analysis can be successfully applied to a data set based on E-State and molecular connectivity descriptors, as is demonstrated in this present work.
II. EXPERIMENTAL DATA AND METHODS

The FDA/CDER Rodent Carcinogenicity Database
The FDA/CDER Rodent Carcinogenicity database was created from summary rat and mouse carcinogenicity study findings for over 1300 compounds that include both industrial chemicals and pharmaceuticals. Rodent carcinogenicity study results in the FDA database were obtained from the National Toxicology Program (NTP) rodent carcinogenicity database, the Lois Gold Carcinogen Potency (CPD) Database [13] , FDA/CDER archives, and the scientific literature. The database includes the name and identification codes, the chemical structure represented as an MDL MOL file, and numeric carcinogenic activity units assigned (discussed below) to each compound.
Acceptance Criteria for Carcinogenicity Studies
Most of the carcinogenicity study results for pharmaceuticals in the FDA database were derived from pharmacology/toxicology and biostatistics reviews and reports in FDA files. The results of carcinogenicity studies in FDA new drug application (NDA) regulatory reviews for marketed products are available under the Freedom of Information Act and are considered non-proprietary. The identity of pharmaceuticals currently under regulatory review as an investigational new drug application (IND) or new drug application (NDA) or drugs that have never been marketed are proprietary and cannot be disclosed without the consent of the sponsor. Proprietary compounds represent approximately 8 % of the total number of carcinogenicity studies in the FDA/CDER database and are coded in this report.
Carcinogenicity Study Design and Analysis
The design of rodent carcinogenicity studies for pharmaceuticals is essentially the same as the design employed for industrial and environmental chemicals and U.S. National Toxicology Program (NTP) rodent carcinogenicity studies. Male and female rats and mice are divided randomly into one or two control and three treatment groups of 50-70 animals per group per species. Historically, the highest dose in the studies analyzed generally approximates the maximum tolerated dose (MTD) in the test species, and is administered daily, usually in the feed or by oral gavage for 2 years. The rodent strains most often used in NTP studies is the inbred Fisher 344 rat and the hybrid B6C3F1 (C3H x C57B16) mouse. In pharmaceutical studies submitted to the FDA, the predominant rodent strains are the Sprague-Dawley derived CD rat, and the CD-1 SwissWebster derived mouse. Despite the long experience in the FDA with these assays, the significance of tumors from lifetime exposure at the maximum tolerated dose, the dose response extrapolation and the relevance of rodent tumors to humans continue to be highly controversial issues.
Classification and Stratification of Rodent Tumor Findings
In studies reviewed by FDA/CDER, tumor findings are classified as positive if either benign and/or malignant findings are statistically significant in pair-wise comparison to concurrent controls by Fisher's Exact Test or equivalent statistical analysis. An adjustment for rare and common events is also applied to tumor findings [14] . Tumors are considered significant if they attained a level of p ≤ 0.01 for common tumors and p ≤ 0.05 for rare tumor types. Rare tumors are those with a spontaneous background incidence rate equal to or less than a 1%. The incidence of benign and malignant tumors (adenomas and carcinomas) are combined and statistically evaluated where appropriate [15] .
Data Transformation: The Numeric Representation of Carcinogenic Activity
Carcinogenicity studies are generally carried out in male and female rats and mice. Each sex/species is considered an individual study cell and therefore a complete battery of carcinogenicity studies for a compound is comprised of 4 study cells. A simplified numerical activity scale was used to quantify and stratify the results of rodent carcinogenicity studies. Compounds that produce statistically significant (by pair-wise comparison) tumors at multiple organ/tissue sites in a study cell were assigned the highest activity value of 50. Compounds that produce statistically significant single site tumors received an activity value of 40 and weaker or equivocal single site responses were assigned an activity value of 30. Studies with no statistically significant treatment-related tumor findings were assigned an activity value of 10. Compounds with 30 or more activity units in 2 or more study cells (2Plus) , that is, having activity that crossed the biological barrier of gender or species, were classified as high risk carcinogens. Compounds with less than 30 activity units in 3 or more study cells were considered not to be high risk carcinogens. Compounds that were tested only in the rat or mouse may also be considered positive if there were significant tumor findings in both males and females. Compounds tested only in one species that have no tumor findings cannot be considered negative without additional information from at least one other study cell. Applying these rules, a training carcinogenicity database was created containing 1022 compounds with 4 cell or equivalent data of which 649 compounds were classified as carcinogenic (High Risk), having tumor findings in at least 2 study cells, and 373 compounds were noncarcinogenic (Low Risk) with negative findings in 3 or more study cells. The greater number of positive compounds is partly a function of the scoring method employed. This scoring method is the same as that used to predict rodent carcinogenicity based on molecular similarity [12] and is a simplification of the multi-cell method used for MCASE-ES rodent carcinogenicity predictions [16] .
The name and structure of proprietary compounds were coded and kept confidential by the FDA. Electrotopological descriptors derived from proprietary molecules were included in the training data set. Although electrotopological state and other topological descriptors employed contain sufficient information for successful modeling they are insufficient to unambiguously recreate a proprietary molecular structure.
A validation experiment employing a total of 50 test compounds that were not part of the MDL ® QSAR (see below) control or training data set were used in this investigation. The 50 test compounds were randomly removed from the 1072 compound rodent carcinogenicity training set. The carcinogenicity model was based on the remaining 1022 training set compounds. The 50 randomly selected test compounds included 38 pharmaceuticals of which 9 (18%) were newer pharmaceuticals currently under regulatory review that are not yet marketed (structures and identity not disclosed) and 12 industrial chemicals. The 50 validation test compounds contained 25 "High Risk" compounds with tumor findings in two or more study cells (2Plus) and 25 "Low Risk" compounds with either no tumor findings or findings in only 1 study cell. Table 3 lists the compounds, their assigned risk level from the FDA/CDER Rodent Carcinogenicity database and the risk level as predicted from the model presented in this work.
III. COMPUTATIONAL METHODS
Descriptors and Descriptor Selection
The MDL ® QSAR module implements molecular topological descriptors available within the Molconn-Z program [17a, 17b]. (A list of publications that illustrate the nature of topological descriptors and their applications is available [17c].) An initial set of 195 topological descriptors was computed by the MDL ® QSAR module for the entire training set of 1022 compounds that were tested for rodent carcinogenicity. The descriptors included atom-type, grouptype, and individual atom E-State and hydrogen E-State indices, molecular connectivity chi indices, kappa shape indices, topological polarity, counts of molecular features (number of rings, number of H-bond donors and acceptors, etc), and others. This initial set was reduced using the following criteria: first, descriptors were only considered that had non-zero value for at least 95% of all compounds and, second, the variance of the descriptor values had to be no less than a certain threshold, set equal to 1.
Model Development
The compounds in the FDA rodent carcinogenicity dataset are characterized either as carcinogenic or noncarcinogenic; therefore, this dataset presents a typical example of a binary classification problem. For the analysis of such datasets, MDL®QSAR employs methods discriminant analysis. The complete description of this method analysis can be found in a number of textbooks and monographs [18, 19] . Herein, we provide a short description of the method pertinent to its implementation within MDL® QSAR.
MDL® QSAR incorporates the algorithms to develop discriminant models and the graphics interface that allows users to input data sets, initiate calculations, analyze and manipulate resulting models. Each model is characterized by rich statistics available to the user. MDL®QSAR implements the entire range of discriminant analysis methods such as parametric, nonparametric kernel, and nearest-neighbor approaches. The classic parametric method of discriminant analysis is applicable in the case of approximately normal within-class distributions. The method generates either a linear discriminant function (the withinclass covariance matrices are assumed to be equal) or a quadratic discriminant function (the within-class covariance matrices are assumed to be unequal). Our initial chemometric analysis of the FDA data set demonstrated that the distribution of the descriptor values did not follow the Gaussian law, which was indicated by the normal distribution hypothesis testing with the confidence level of 0.01. When the distribution is not assumed to follow a particular law or is assumed to be other than the multivariate normal distribution, nonparametric methods can be used to derive classification criteria. The nonparametric methods available within the MDL® QSAR include the kernel and knearest-neighbor (kNN) methods. The main types of kernels implemented in MDL® QSAR include uniform, normal, Epanechnikov, biweight, or tri-weight kernels, which are used to estimate the group specific density at each observation.
In general, either Mahalanobis or Euclidean distances can be used to determine proximity between compound-vectors in multidimensional descriptor space. When the k-nearestneighbor method is used, the Mahalanobis distances are based on the pooled covariance matrix. When a kernel method is used, the Mahalanobis distances are based on either the individual within-group covariance matrices or the pooled covariance matrix. Either the full covariance matrix or the diagonal matrix of variances can be used to calculate the Mahalanobis distances. In our studies, various combinations of model building preferences have been explored to achieve a model with the highest accuracy. The performance of each candidate model was assessed by making use of the prediction error rate in the training set (i.e., probabilities of misclassification). For each model, the true positive (TP), true negative (TN), false positive (FP), and false negative (FN) rates were studied both for resubstitution analysis as well as those resulting from leaveone-out cross-validation. The computation of each model studied took several seconds on a Pentium 4 processor with 2.8 MHz and 1 Gb memory.
IV. COMPUTATIONAL STUDIES
The task of finding the best model falls into two interconnected parts: the search for the best subset of descriptors and the selection of the type and optimal parameters of the model. Both these subtasks admit no formal algorithmic solution and require some experimentation to achieve the best solution. In our studies, more than 3000 discriminant analysis models were built in total, using different criteria for descriptor reduction and various parameters of discriminant analysis as described in the Methods Section. The best model included 53 variables ( Table 1) and was characterized by the following parameters: normal kernel; smoothing parameter of 2; Mahalanobis distance to determine proximity; distance calculations based on the full individual within-group covariance matrices; prior probabilities set to 0.5.
The correct classification rates for the best discriminant model, which is supplied with MDL® QSAR, are shown in Table 2 . Total accuracy of the model, both for C resubstitution and LOO cross-validation analyses is shown as well as separate data for the test set prediction of carcinogenic (high risk carcinogens) as well as noncarcinogenic (low risk carcinogen) compounds.
V. DISCUSSION
Risk Mitigation
The modeling approach in this study was chosen specifically for a risk analysis approach. Unexpected results in long-term carcinogenicity bioassays on a new drug candidate can be extremely costly in time, money, and market viability. With today's technology, applicants must carry the risk of long-term carcinogenicity well into phase 2-3 clinical development with little or no mitigation. At this stage of development, even a single failure can result in a huge loss: the late-stage non-approval of a drug can mean the loss of $700 million or more [20] , and represent the loss of six to eight years of development effort.
The chosen modeling paradigm, in its selection of chemical structure variable type, its identification of a real world risk threshold in endpoint definition, and its straightforward statistical method, can be called 'actuarial' in approach. This allows the user of the model to view various confidence and applicability measures and restrict acceptable ranges as desired. Two such calculated metrics are the Distance and the Probability of Membership in Class. The Table 1 . Descriptors selected in the best model for the prediction of carcinogenicity. The descriptors appear in groupings that relate to their structure information content. A ranking is also given, based on descending order of F-value for inclusion of the descriptor in the model. A brief definition is given for each descriptor along with an illustration for a selected few descriptors. For more specific information on structure interpretation see the appropriate references [6-11,17d].
Index
Rank Description
Low Order Chi Indices
Encode degree of skeletal branching and molecular size. Low order indices x0 and x1 increase with molecular size and decrease with increased branching. Chi 2 (x2) shows the greatest sensivity to differences in branching and increases with branching. calculated Distance shows whether the subject compound vector is adequately represented within the historic variance of chemical structure descriptors. The Probability of Membership in Class is a measure of how well the historic knowledge is able to discriminate high risk compounds from low risk compounds within the nearest space of the subject compound vector.
Probability of Membership in Class
The results for prediction are given in Table 3 along with the original rodent data. The prediction rates are 84% correct for low risk and 76 % for high risk with an overall rate of 80% correct. Incorrect predictions are marked in bold. In this present study, we found that by placing limits on probability in class we could trade overall coverage for accuracy. By placing a minimum of 60% Probability-in-Class on our 50 compound test set, overall coverage was reduced to 76%, Sensitivity rose from 76% to 87%, Specificity remained essentially constant at 84% (83%), and Concordance improved from 80% to 84% (See Table 4 ). By placing a minimum of 65% Probability in Class, Coverage was 70%, Sensitivity 93%, Specificity 86% and Concordance 89% (See Table 5 ). Exercising this option allows a flexibility in how the model is employed, perhaps allowing a wider range of acceptable probability in screening large compound libraries to glean general characteristics, while restricting this range when assessing safety risks in lead compounds for better confidence.
Distance Measure
MDL®QSAR evaluates two quantitative measures of applicability of data models to new observations: 1. regression 
Having chosen the distance in the observation space, one should also decide which distances are to be considered "large" or "small". In the case of regression models, it is natural to use an obvious analogy between outliers in the training set and "far-flung" observations. First note that the sum of Mahalonobis distances for all observations from the training set is p(n -1). Consider quantity d = M / (n -1) which is referred to as centered leverage value and for observations from the training set lies between 0 and 1. Based on the rules for separation of outliers in the observation space, which are recommended in regression analysis, the degree of applicability of a regression model to an object that is not a member of the training set is evaluated in MDL®QSAR as follows:
If d exceeds p/n, its average across the training set, more than twofold, one should treat the prediction for such a case with caution.
If d > 0.5, the degree of applicability of a model to an object is taken to be very low; if 0.2 < d ≤ 0.5 low, and if d ≤ 0.2 we consider it optimal to use the model.
For discriminant analysis models, such as the model contained in the MDL® Carcinogenicity Module, similar methods for separation of outliers are not used. In order to partition distances into "large" and "small", an approach to data standardization is applied that is traditional for statistics. Suppose that distance D (Euclidian, see definition above) is normally distributed across the general population of data. Then, the standardized distance d 1 (the difference between the distance and its sample mean over the training set) divided by the sample estimate of mean-square deviation, will approximately follow a normal distribution with parameters 0, 1. Thus probabilities for d 1 to fall into one or another interval of the real axis are found from the tabulated values of the Laplace function. For example, consider points x 0 = 1.65 and x 1 = 2.33 marked on the axis, such that the probability to fall to the left of them is, respectively, 0.95 and 0.99. If a new observation produces value d 1 ≥ x 1 , the degree of applicability of a model to such an object may be taken to be very low; if x 0 ≤ d 1 < x 1 -low.
VI. CONCLUSIONS
The FDA/CDER rodent carcinogenic database provides a sound basis for development of a model for the prediction of carcinogenicity risk. The combination of the experimental data and the experience in the FDA provided the basis for qualifying 1072 compounds for the database. The MDL®QSAR software provided a useful basis for calculating the molecular descriptors and performing the discriminant analysis to establish a classification algorithm. The topological structure descriptors included electrotopological state (E-State) descriptors and molecular connectivity chi indices that have been shown to provide a sound basis for classifying molecular structures. A nonparametric method was used to obtain the final model based on the normal kernel method. Descriptors were selected by examining models with varying numbers of descriptors and deciding upon the model with the best classification statistics on the training set. The discriminant model presented here demonstrates good prediction statistics on the external validation test set of fifty compounds with sensitivity of 76% and specificity of 84% in addition to concordance of 80%. This test set includes 38 pharmaceuticals and 12 industrial chemicals. Nine of the pharmaceuticals are newer compounds that are still under regulatory review and confidential. Twenty-five of the test set compounds are considered high risk. Based on these results the model appears useful as an indicator of potential carcinogenicity risk for candidate molecules in a design process and for regulatory decision support.
Data transformation is an essential component in the QSAR modeling of carcinogenicity from rodent bioassay. This process converts tumor incidence findings into weighted numerical form with the highest score given to multi-site and trans-species tumor findings. This simulates aspects of the weight of evidence process used in regulatory risk analysis. Tumor site is not considered in this modeling process because there is poor tumor site concordance between rats and mice making it a poor factor for QSAR modeling [21] .
Converting molecular structure into electrotopological state (E-State) descriptors and molecular connectivity chi indices also provides a means for modeling proprietary molecular structures that does not disclose the exact structure and identity of proprietary molecules. In this report proprietary compounds were included in the training data set and in the 50 test compounds. The name and structure of proprietary compounds was encoded and kept confidential by the FDA. The proprietary structure information descriptors contained sufficient information for successful modeling but are insufficient to unambiguously recreate a molecular structure, making this a valuable tool for data sharing while preserving confidentiality.
Computational toxicology combines databases and chemoinformatic data mining techniques with statistical methods to identify relationships between chemical structures and toxicological activities. Computational or predictive toxicology software programs are a means of evaluating knowledge accumulated from decades of toxicology studies to provide effective regulatory and product development decision support information. This approach is especially useful for prioritizing potential hazard and identifying data gaps in situations where toxicological data is limited, e.g., indirect food additives or contaminants and degredants/contaminants in the pharmaceutical manufacturing process. In drug development, the application of combinatorial chemistry and high throughput screening has resulted in an unprecedented increase in the number of compounds identified with potentially desirable pharmacological properties. The selection of lead compounds for development is currently hampered by limitations in the available toxicity screening methods. Making better use of accumulated scientific knowledge incorporated in predictive software is one way to minimize toxicity related drug failures and improve pharmaceutical risk management. Identifying serious potential toxicity early in the drug development process before significant investments in time and resources are expended is a major goal for FDA/CDER and the pharmaceutical industry. A current cause for concern is that too many drugs are failing late in the development process in phase III either for lack of efficacy or toxicity. It is estimated that 20% of total R&D costs per drug are spent on compounds that ultimately fail due to unfavorable ADME/Toxicity. The selection of drug candidates with better safety profiles will also reduce the regulatory review burden and speed the approval process by reducing the number of drugs submitted with serious safety issues that necessitate multiple review cycles or result in termination. Review resources expended for drugs that never make it to market are lost and could better be used for compounds that will succeed.
Computational or predictive toxicology has potential regulatory and drug development applications that can ultimately benefit the public health as well as refine and reduce the use of animals in the assessment of safety.
